Truist Financial Issues Pessimistic Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price target cut by Truist Financial from $16.00 to $15.00 in a research report report published on Monday,Benzinga reports. They currently have a hold rating on the stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, December 19th. Macquarie started coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. UBS Group upped their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group lifted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Trading Down 2.5 %

NYSE:MD opened at $12.81 on Monday. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a fifty day simple moving average of $14.35 and a 200-day simple moving average of $11.49. The company has a market capitalization of $1.10 billion, a PE ratio of -4.19, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the previous year, the business posted $0.29 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Institutional Trading of Pediatrix Medical Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Nordea Investment Management AB lifted its position in Pediatrix Medical Group by 51.6% during the fourth quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock valued at $3,504,000 after buying an additional 89,739 shares in the last quarter. Everence Capital Management Inc. raised its stake in shares of Pediatrix Medical Group by 7.5% in the 4th quarter. Everence Capital Management Inc. now owns 13,840 shares of the company’s stock valued at $182,000 after acquiring an additional 960 shares during the period. Principal Financial Group Inc. raised its stake in shares of Pediatrix Medical Group by 14.1% in the 3rd quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after acquiring an additional 63,581 shares during the period. Franklin Resources Inc. acquired a new position in shares of Pediatrix Medical Group during the 3rd quarter valued at $598,000. Finally, Barclays PLC boosted its position in Pediatrix Medical Group by 302.9% during the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after purchasing an additional 106,817 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.